TY  - JOUR
AU  - Dimopoulos, Meletios A
AU  - Dytfeld, Dominik
AU  - Grosicki, Sebastian
AU  - Moreau, Philippe
AU  - Takezako, Naoki
AU  - Hori, Mitsuo
AU  - Leleu, Xavier
AU  - LeBlanc, Richard
AU  - Suzuki, Kenshi
AU  - Raab, Marc-Steffen
AU  - Richardson, Paul G
AU  - Popa McKiver, Mihaela
AU  - Jou, Ying-Ming
AU  - Shelat, Suresh G
AU  - Robbins, Michael
AU  - Rafferty, Brian
AU  - San-Miguel, Jesús
TI  - Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
JO  - The New England journal of medicine
VL  - 379
IS  - 19
SN  - 1533-4406
CY  - Waltham, Mass.
PB  - MMS
M1  - DKFZ-2019-00106
SP  - 1811 - 1822
PY  - 2018
AB  - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival.A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95
KW  - Antibodies, Monoclonal, Humanized (NLM Chemicals)
KW  - Immunologic Factors (NLM Chemicals)
KW  - elotuzumab (NLM Chemicals)
KW  - Thalidomide (NLM Chemicals)
KW  - Dexamethasone (NLM Chemicals)
KW  - pomalidomide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30403938
DO  - DOI:10.1056/NEJMoa1805762
UR  - https://inrepo02.dkfz.de/record/142330
ER  -